APA (7th ed.) Citation

Behringer, K., Goergen, H., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., . . . Engert, A. (2015). Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial. The lancet, 385(9976), . https://doi.org/10.1016/S0140-6736(14)61469-0

Chicago Style (17th ed.) Citation

Behringer, Karolin, et al. "Omission of Dacarbazine or Bleomycin, or Both, from the ABVD Regimen in Treatment of Early-stage Favourable Hodgkin's Lymphoma (GHSG HD13): An Open-label, Randomised, Non-inferiority Trial." The Lancet 385, no. 9976 (2015). https://doi.org/10.1016/S0140-6736(14)61469-0.

MLA (9th ed.) Citation

Behringer, Karolin, et al. "Omission of Dacarbazine or Bleomycin, or Both, from the ABVD Regimen in Treatment of Early-stage Favourable Hodgkin's Lymphoma (GHSG HD13): An Open-label, Randomised, Non-inferiority Trial." The Lancet, vol. 385, no. 9976, 2015, https://doi.org/10.1016/S0140-6736(14)61469-0.